We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Synthetic Biologics

News List

Synthetic Biologics Discontinues Study of SYN-010 in IBS-C Patients americanpharmaceuticalreview
October 12, 2020
Synthetic Biologics has announced the results of a planned interim futility analysis of the investigator-sponsored Phase 2b clinical study of SYN-010 being conducted by Cedars-Sinai Medical Center (CSMC).
Synthetic Biologics Announces Positive FDA Meeting on SYN-004 Development americanpharmaceuticalreview
November 29, 2018
Synthetic Biologics announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 ......
Synthetic Biologics’ SYN-004 secures FDA breakthrough therapy status pharmaceutical-technology
May 16, 2017
Synthetic Biologics has secured breakthrough therapy designation for SYN-004 (ribaxamase) from the US Food and Drug Administration (FDA) to treat Clostridium difficile infection (CDI).